Clinical CAR-T Capabilities
Challenge from the Client
A global manufacturer of biopharmaceuticals was launching clinical trials of a new myeloma CAR-T therapy and needed to serve its clinical cancer patient population in the timeliest manner, by the end of a year.
Our Approach & Solution
Utilizing our proprietary service and product technologies, IPS worked to masterplan our client’s requirements by executing a one-week Inceptioneering study to obtain initial funding followed by the deployment of our iCON ÜBERcellFLEX PODs to put the proper assets in place and meet the critical schedule milestones.
The new facility and equipment assets were conceived, designed, fabricated, acceptance tested, commissioned and qualified to receive 1st patient samples in less than a year.